Prostate:高风险前列腺癌病人在首发症状时的预后参数分析

2017-11-14 AlexYang MedSci原创

高风险前列腺癌可以由病人的格林森得分(GS)、前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定,但是由于该病的异质性,一个新的标记是需要的。最近,有研究人员评估了在患有高风险前列腺癌病人中,是否由穿刺活检确定的前列腺导管内癌(IDC-P)是无进展自由生存(PFS)和癌症特异生存(CSS)的不良预后参数。研究人员回顾性的评估了1991年到2005年经历根治性前列腺癌切除术的患有高风险前列腺

高风险前列腺癌可以由病人的格林森得分(GS)、前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定,但是由于该病的异质性,一个新的标记是需要的。最近,有研究人员评估了在患有高风险前列腺癌病人中,是否由穿刺活检确定的前列腺导管内癌(IDC-P)是无进展自由生存(PFS)和癌症特异生存(CSS)的不良预后参数。研究人员回顾性的评估了1991年到2005年经历根治性前列腺癌切除术的患有高风险前列腺癌的204名病人,地点是在日本名古屋大学和其附属医院。

研究发现,平均的跟踪调查时间为108个月(范围:11-257个月)。48名病人(24%)表现出了疾病的恶化。34名病人(17%)在跟踪调查期间因该病死亡。在74(36%)个穿刺活检样本中检测到了IDC-P。IDC-P阴性案例的5年、10年和15年CSS比例分别为3.2%、9.0%和23.7%;而IDC-P阳性案例的比例分别为23.9%、33.7%和52.7%(P=0.0001)。在Fine 和Gray's模型中,PFS与IDC-P、与癌症有关的最大核心比例以及cT阶段均显著相关(P=0.013, P=0.003, P=0.007)。在CSS的Fine 和Gray's模型中,只有IDC-P是显著的(P=0.027)。在多变量Cox回归分析中,IDC-P(P=0.04;风险比(HR),1.95)和与癌症有关最大核心比(P=0.021; HR, 0.43)均为预测总生存(OS)的显著因子。

最后,研究人员指出,穿刺活检中的IDC-P的出现是患有高风险前列腺癌且经历根治性前列腺癌切除术病人的PFS、CSS和OS的预后因子。当在穿刺活检样本中发现IDC-P时,多种方式的术前和术后治疗是需要的。

原始出处:

Kato M, Kimura K, Hirakawa A et al. Prognostic parameter for high risk prostate cancer patients at initial presentation. Prostate. 2 Nov 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2018270, encodeId=4eca20182e08b, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 24 02:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862041, encodeId=7f7f186204160, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 07 19:00:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364257, encodeId=5ff1136425ec9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601943, encodeId=376f1601943ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261578, encodeId=b8f92615e8a5, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Nov 15 23:31:47 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261338, encodeId=c781261338e9, content=高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Nov 14 22:35:18 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261317, encodeId=eaa626131ea8, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Nov 14 21:13:23 CST 2017, time=2017-11-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2018270, encodeId=4eca20182e08b, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 24 02:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862041, encodeId=7f7f186204160, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 07 19:00:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364257, encodeId=5ff1136425ec9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601943, encodeId=376f1601943ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261578, encodeId=b8f92615e8a5, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Nov 15 23:31:47 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261338, encodeId=c781261338e9, content=高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Nov 14 22:35:18 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261317, encodeId=eaa626131ea8, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Nov 14 21:13:23 CST 2017, time=2017-11-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2018270, encodeId=4eca20182e08b, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 24 02:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862041, encodeId=7f7f186204160, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 07 19:00:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364257, encodeId=5ff1136425ec9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601943, encodeId=376f1601943ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261578, encodeId=b8f92615e8a5, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Nov 15 23:31:47 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261338, encodeId=c781261338e9, content=高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Nov 14 22:35:18 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261317, encodeId=eaa626131ea8, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Nov 14 21:13:23 CST 2017, time=2017-11-14, status=1, ipAttribution=)]
    2017-11-16 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=2018270, encodeId=4eca20182e08b, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 24 02:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862041, encodeId=7f7f186204160, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 07 19:00:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364257, encodeId=5ff1136425ec9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601943, encodeId=376f1601943ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261578, encodeId=b8f92615e8a5, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Nov 15 23:31:47 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261338, encodeId=c781261338e9, content=高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Nov 14 22:35:18 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261317, encodeId=eaa626131ea8, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Nov 14 21:13:23 CST 2017, time=2017-11-14, status=1, ipAttribution=)]
    2017-11-16 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2018270, encodeId=4eca20182e08b, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 24 02:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862041, encodeId=7f7f186204160, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 07 19:00:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364257, encodeId=5ff1136425ec9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601943, encodeId=376f1601943ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261578, encodeId=b8f92615e8a5, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Nov 15 23:31:47 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261338, encodeId=c781261338e9, content=高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Nov 14 22:35:18 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261317, encodeId=eaa626131ea8, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Nov 14 21:13:23 CST 2017, time=2017-11-14, status=1, ipAttribution=)]
    2017-11-15 131****2916

    不错的文章值得推荐

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2018270, encodeId=4eca20182e08b, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 24 02:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862041, encodeId=7f7f186204160, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 07 19:00:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364257, encodeId=5ff1136425ec9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601943, encodeId=376f1601943ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261578, encodeId=b8f92615e8a5, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Nov 15 23:31:47 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261338, encodeId=c781261338e9, content=高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Nov 14 22:35:18 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261317, encodeId=eaa626131ea8, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Nov 14 21:13:23 CST 2017, time=2017-11-14, status=1, ipAttribution=)]
    2017-11-14 有备才能无患

    高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的.

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2018270, encodeId=4eca20182e08b, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 24 02:00:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862041, encodeId=7f7f186204160, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 07 19:00:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364257, encodeId=5ff1136425ec9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601943, encodeId=376f1601943ee, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Nov 16 12:00:00 CST 2017, time=2017-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261578, encodeId=b8f92615e8a5, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Nov 15 23:31:47 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261338, encodeId=c781261338e9, content=高风险前列腺癌可以由病人的格林森得分(GS).前列腺特异性抗原水平(PSA)和临床T(cT)阶段进行确定.但是由于该病的异质性.一个新的标记是需要的., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Nov 14 22:35:18 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261317, encodeId=eaa626131ea8, content=很好的文章.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Nov 14 21:13:23 CST 2017, time=2017-11-14, status=1, ipAttribution=)]
    2017-11-14 清风拂面

    很好的文章.谢谢分享

    0

相关资讯

Br J Cancer:PICK1可抑制前列腺癌的骨转移

众所周知,TGF-β信号的组成性激活是前列腺癌(PCa)骨转移发生的机制。蛋白质与PRKCA1(PICK1)的相互作用是TGF-β途径的关键负调节因子。然而,PICK1在PCa骨转移中的临床意义和生物学作用仍不明确。本研究中,研究人员在198例PCa患者中通过免疫组织化学(IHC)评估PICK1表达。统计学分析探讨PICK1表达与PCa患者临床病理特征的相关性。PICK1的生物学作用在体外PC-3

Nat commun:在去势难治性前列腺癌中,硫氧还蛋白可以防止雄激素受体诱导的氧化还原损伤

雄激素阻断(AD)治疗失败常常会导致终极的和难治愈的去势难治性前列腺癌(CRPC)。最近,有研究人员展示了氧化还原保护性蛋白-硫氧还蛋白-1(TRX1)随着前列腺癌的恶化以及在雄激素阻断的CRPC细胞中增加,这个现象表明了CRPC对TRX1具有增强的依赖性。研究人员发现,TRX1抑制作用可通过shRNA或者PX-12(在前列腺癌中未测试)来妨碍CRPC细胞的生长,并且比它们相对应的雄激素依赖的物质

Eur J Cancer:健康生活品质得分与去势难治性前列腺癌治疗临床结果相关性分析

最近,有研究人员探究了健康生活品质得分(HRQoL)(基点以及随着时间的变化)和去势难治性前列腺癌(mCRPC)治疗临床结果(总生存(OS)/影像学无进展生存(rPFS))之间的关系。研究人员在阶段3试验中评估了HRQoL、OS和rPFS,并且在mCRPC化疗或者化疗后(AFFIRM; NCT00974311)中比较了恩杂鲁胺和安慰剂(PREVAIL;NCT01212991)的上述指标。研究人员利

BMC Cancer:澳大利亚男性对前列腺癌诊断和护理看法的研究

据维多利亚前列腺癌登记处(澳大利亚)透露,在维多利亚一个地区的诊断为前列腺癌的男性的生存率要比大城市墨尔本诊断为前列腺癌男性的生存率低。最近,有研究人员探究了居住在地区和大城市中诊断为前列腺癌男性对前列腺癌诊断、治疗和护理的看法和经历,并且也同时探究了那些没有进行上述诊断的男性。研究人员的目的是为持续性的前列腺健康护理改善提供证据。研究人员利用了深度访谈定量方法来获得解释和意义,并且访问了21名男

Prostate:前列腺癌中的雌激素受体信号分析

雄激素受体(AR)是前列腺癌预防和治疗的经典靶标。但是,有研究表明雌激素和它们的受体同样涉及到了前列腺癌发展和肿瘤恶化。最近,有研究人员回顾了最近的实验和临床数据,从而来阐释雌激素和它们的受体对前列腺致瘤和肿瘤恶化产生作用的病理机制。研究发现,雌激素受体(ERβ)是人类前列腺中最普遍的ER,然而雌激素受体(ERα)的分布限制在前列腺上皮基底细胞和基质细胞中。在高等级前列腺上皮内瘤(HGPIN)中,

BMC Urol:加拿大男性对前列腺癌积极监控的观点研究

在前列腺癌中,被诊断为低风险疾病的男性也许可以通过积极的监控(AS)来进行指导。最近,有研究人员探究了患有前列腺癌的男性对积极监控的观点,从而鉴定影响他们决定的因素,并且协助健康专业人员就该选项进行对话。研究人员在加拿大的7个城市中诊断为前列腺癌并且适合积极监控的男性(N=52)中进行了7次焦点组访谈。关于他们对积极监控的理解、影响他们决定的因素以及对积极监控的经历,研究人员记录了他们的观点。另外